Clinical trials: Vascular And Immunologic Diseases
Neurological Disease
Development, Reliability and Validity of the Telerehabilitation Satisfaction Questionnaire- TrSQ
Parkinson's disease (PD), stroke, and Multiple Sclerosis (MS) are the most common neurological diseases. Today, physiotherapy and rehabilitation approaches together with optimal medical and surgical treatment form the basis of…
- Trial name
- NCT05520554
- Testing
- Development of the Telerehabilitation Satisfaction Questionnaire
- Where
- Turkey (Türkiye)
- Volunteers
- 63 people
- Sponsor
- Gazi University
Multiple Myeloma, Cutaneous Lymphoma
ATRA Plus G-CSF for Mobilization of Hematopoietic Stem and Progenitor Cells
Hematopoietic stem and progenitor cells (HSPC) are used for transplantation in patients undergoing high dose therapy for the treatment of a range of cancers.
- Trial name
- NCT00400556
- Testing
- ATRA plus G-CSF (filgrastim, NEUPOGEN (R)) combination
- Where
- Australia
- Volunteers
- 6 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Refractory Multiple Myeloma
Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
RATIONALE: Aurora A kinase inhibitor MLN8237 and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT01034553
- Testing
- Aurora A kinase inhibitor MLN8237, bortezomib
- Where
- 6 sites in United States
- Volunteers
- 26 people
- Sponsor
- Mayo Clinic
Sarcoma, Adenocarcinoma
Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease
The study is designed to determine if high doses of intravenous ascorbic acid (vitamin C) can be effective in managing solid tumor diseases.
- Conditions
- Sarcoma, Adenocarcinoma, Carcinoma, Multiple Myeloma
- Trial name
- NCT01125449
- Testing
- Ascorbic acid (vitamin C)
- Where
- United States
- Sponsor
- Situs Cancer Research Center
Multiple Myeloma Refractory
Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients
The goal of this clinical trial is to learn if the antibody drug HuL001, combined with Lenalidomide/Dexamethasone works to treat Multiple Myeloma patients.
- Trial name
- NCT07210047
- Testing
- HuL001, Lenalidomide/Dexamethasone
- Where
- Taiwan
- Volunteers
- 21 people
- Sponsor
- HuniLife Biotechnology, Inc.
Multiple Myeloma
Clarithromycin in Multiple Myeloma Induction Therapy
This study evaluates the potential synergic anti-myeloma activity of clarithromycin when combined with VCD induction therapy in patients with newly diagnosed multiple myeloma.
- Trial name
- CLAIM (NCT02573935)
- Testing
- Clarithromycin, VCD induction therapy
- Where
- 7 sites in Denmark
- Volunteers
- 58 people
- Sponsor
- Henrik Gregersen
Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma
Meloxicam vs Placebo for Mobilization
This research study is evaluating a drug called meloxicam to see if it provides a benefit to people receiving Autologous Hematopoietic Stem Cell Transplantation (AHSCT).
- Conditions
- Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Multiple Myeloma, Hematopoietic Stem Cells
- Trial name
- NCT02003625
- Testing
- GCSF, meloxicam
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Massachusetts General Hospital
Multiple Myeloma, Hematopoietic Stem Cell Mobilization
Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients
This is a prospective, randomized, two-arm, multicenter, exploratory study aimed at evaluating the efficacy and safety of the combination of etoposide, cytarabine and Pegfilgrastim (EAP regimen) for mobilizing hematopoietic stem…
- Trial name
- NCT06520176
- Testing
- Etoposide, Cytarabine, Pegfilgrastim
- Where
- 16 sites in China
- Volunteers
- 99 people
- Sponsor
- The Affiliated People's Hospital of Ningbo University
POEMS Syndrome, Amyloidosis
A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis
A Clinical Study on the Safety and Effectiveness of CD19/BCMA Chimeric Antigen Receptor T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis
- Conditions
- POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, Vasculitis
- Trial name
- NCT05263817
- Testing
- CD19/BCMA CAR T-cells
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Zhejiang University
Lymphoma, Non-Hodgkin, Multiple Myeloma
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a…
- Conditions
- Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
- Trial name
- TAPUR (NCT02693535)
- Testing
- Sunitinib (CLOSED TO ENROLLMENT), Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT), Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT)
- Where
- 181 sites in United States, Puerto Rico
- Volunteers
- 4,200 people
- Sponsor
- American Society of Clinical Oncology
Multiple Myeloma
Oral ONC201 in Relapsed/Refractory Multiple Myeloma
This was a Phase 1/2 open-label study of ONC201 administered orally once every week in combination with dexamethasone in adults with relapsed/refractory multiple myeloma.
- Trial name
- NCT02863991
- Testing
- ONC201, Dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Jazz Pharmaceuticals
Hereditary Angioedema, Pediatric
Berotralstat Treatment in Children With Hereditary Angioedema
The purpose of this study is to evaluate the pharmacokinetics (PK), safety and effectiveness of berotralstat to determine the appropriate weight-based dose for pediatric participants 2 to < 12 years of age for prophylactic…
- Trial name
- APeX-P (NCT05453968)
- Testing
- Berotralstat
- Where
- 15 sites in Austria, Canada and 8 more
- Volunteers
- 29 people
- Sponsor
- BioCryst Pharmaceuticals
Multiple Myeloma
APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma
The purpose of this study is to test the safety and efficacy of AUTO2, a CAR T Cell Treatment Targeting BCMA and TACI, in Patients with Relapsed or Refractory Multiple Myeloma.
- Trial name
- APRIL (NCT03287804)
- Testing
- AUTO2
- Where
- 4 sites in Netherlands, United Kingdom
- Volunteers
- 12 people
- Sponsor
- Autolus Limited
Multiple Myeloma
Bendamustine Plus Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate efficacy and safety of the combination regimen of bortezomib-bendamustine-dexamethasone in patients with relapsed or refractory multiple myeloma
- Trial name
- BBD (NCT01168804)
- Testing
- bendamustine plus bortezomib plus dexamethasone
- Where
- 8 sites in Austria, Czechia
- Volunteers
- 79 people
- Sponsor
- Austrian Forum Against Cancer
Multiple Myeloma
Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma
The primary objective was to compare the progression-free survival of transplant ineligible patients newly diagnosed with multiple myeloma who were treated with carfilzomib, melphalan and prednisone (CMP) or with Velcade®…
- Trial name
- CLARION (NCT01818752)
- Testing
- Carfilzomib, Bortezomib, Melphalan
- Where
- 213 sites in United States, Argentina and 28 more
- Volunteers
- 955 people
- Sponsor
- Amgen
Urticaria
A Study of Quilizumab Versus Placebo in Patients With Refractory Chronic Spontaneous Urticaria
This multicenter, randomized, double-blind, placebo-controlled, parallel-group study will assess the efficacy and safety of additional quilizumab therapy in adult patients with Chronic Spontaneous Urticaria resistant to…
- Trial name
- NCT01987947
- Testing
- Quilizumab
- Where
- 3 sites in Canada, Germany
- Volunteers
- 32 people
- Sponsor
- Genentech, Inc.
Chronic Kidney Diseases, Diabetes Mellitus
Prevalence of Chronic Kidney Disease (CKD) and Risk Factors in Sub-Saharan Africa
Prospective cross-sectional study at the outpatient clinic (OPC) of the Bagamoyo District Hospital (BDH) in Tanzania. Assessment of basic epidemiological data (Point prevalence and risk factors) on CKD with simple clinical…
- Conditions
- Chronic Kidney Diseases, Diabetes Mellitus, Hypertension, Tuberculosis
- Trial name
- RenalOne (NCT03458338)
- Testing
- estimated glomerular filtration rate and albuminuria
- Where
- Switzerland
- Volunteers
- 1,006 people
- Sponsor
- University Hospital, Basel, Switzerland
Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma
Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
This phase I trial studies the side effects and best dose of filanesib when given together with carfilzomib in treating patients with multiple myeloma or plasma cell leukemia that has returned or does not respond to treatment.
- Conditions
- Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Trial name
- NCT01372540
- Testing
- Carfilzomib, Filanesib, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- M.D. Anderson Cancer Center
Protamine Allergy, Protamine Adverse Reaction
Serum Tryptase Levels During Cardiac Surgery, Diagnosis and Treatment Decisions for Allergic Reactions
The investigators aim to assess tryptase test efficacy for measuring the allergic response to protamine during cardiac bypass surgery.
- Trial name
- NCT02644785
- Testing
- protamine
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Mustafa Kemal University
Multiple Myeloma, Plasma Cell Disorder
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.
- Trial name
- NCT04879043
- Testing
- HDP-101
- Where
- 24 sites in United States, Germany and 3 more
- Volunteers
- 78 people
- Sponsor
- Heidelberg Pharma AG
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.